A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
Status:
Not yet recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the tissue distribution of guselkumab and risankizumab
in healthy participants (Part 1) and psoriatic arthritis (PsA) participants (Part 2).